TGTracie Gilliland

Tracie Gilliland

*This is an algorithmically generated author record based on publicly available information.

Tracie Gilliland has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An Observational Study of Human Umbilical Cord Tissue Allografts for Paraspinal Muscle and Entheses Defects in the Thoracic and Lumbar Regions

    by Conrad Tamea, Jeff Buchalter, Jason Capra, Tracie Gilliland, Naomi Lambert, Alexis Lee, Tyler Barrett

    Introduction: With age and injury, the infiltration of fat in the paraspinal muscles can cause degeneration, disorganizing the structural integrity of the connective tissue and causing lower back pain (LBP). Human umbilical cord tissue allografts (UCTAs) have a collagen-rich matrix with various extracellular matrix (ECM) components that can replace damaged connective tissue. The objective of this paper is to analyze the preliminary findings from an observational repository on UCTAs for the supplementation of degenerated tissue in thoracic and lumbar paraspinal muscles refractory to standard conservative methods through patient-reported scales. Materials and Methods: A total of 117 patients from an observational repository were identified with paraspinal muscle degeneration. Patients received one to three applications of UCTAs; outcomes were tracked using the Numeric Pain Rating Scale (NPRS), the Western Ontario and McMaster University Arthritis Index (WOMAC), and the Quality-of-Life Scale (QOLS). Results: All groups showed positive improvement in the NPRS and WOMAC scales. Multi-application groups revealed statistically significant differences in the analyses. No adverse events or complications were reported. Discussion: Limitations included a lack of a control group, non-standardized application protocol, and the increase in recall and response bias due to using patient-reported measures. Conclusions: This pilot investigation presents the preliminary effectiveness necessary in hypothesis generation for continued research through randomized controlled trials to validate efficacy, establish optimal dosage protocols, and compare UCTAs to other conservative interventions.

  • Open Access

    Human Umbilical Cord Tissue Allografts in Chondromalacia of the Shoulder

    by Albert Lai, Jeff Buchalter, Jason Capra, Heather Johnson, Lonnie Peets, Tracie Gilliland, Laura Melsheimer, Renne Dodd, Naomi Lambert, Alexis Lee, et al.

    Introduction: With age and injury, the infiltration of fat in the paraspinal muscles can cause degeneration, disorganizing the structural integrity of the connective tissue, causing lower back pain (LBP). Human umbilical cord tissue allografts (UCTa) have a collagen-rich matrix with various ECM components that can replace damaged connective tissue. The objective of this study is to evaluate preliminary findings on the safety and efficacy of UCTa for the supplementation of degenerated tissue in thoracic and lumbar paraspinal muscles refractory to standard conservative methods. Materials and Methods: A total of 141 patients from an observational repository were identified with paraspinal muscle degeneration. Patients received one to three applications of UCTa, outcomes were tracked using the Numeric Pain Rating Scale, the Western Ontario and McMaster University Arthritis Index, and the Quality-of-Life Scale. Results: All groups showed positive improvement in the NPRS and WOMAC scales. Multi-application groups revealed statistically significant differences in the analyses. No adverse events or complications were reported. Discussion: Limitations included a lack of a control group and the increase of recall and response bias due to using patient-reported measures. Conclusion: This pilot investigation highlights the need for continued research through randomized controlled trials to validate efficacy, establish optimal dosage protocols, and compare UCTa to other conservative interventions.

  • Open Access

    Human Umbilical Cord Tissue Allografts for Cervical Paraspinal Muscle and Entheses

    by Conrad Tamea, Jeff Buchalter, Jason Capra, Tracie Gilliland, Heather Johnson, Lonnie Peets, Naomi Lambert, Alexis Lee, Tyler Barrett

    Introduction: Cervical paraspinal enthesopathy is characterized by fatty infiltration and muscle degeneration; current methods only provide symptomatic relief or involve significant postoperative complications. This study provides preliminary results for the clinical potential of umbilical cord tissue allografts (UCTa) in patients with cervical paraspinal enthesopathy and degeneration refractory to standard care. Materials and Methods: The Numeric Pain Rating Scale, Western Ontario and McMaster University Arthritis Index, and Quality of Life Scale were used to measure outcomes of thirty-one patients with cervical paraspinal degeneration from an observational repository who received one to three UCT allograft applications. The Wilcoxon Signed-Rank test, Mann-Whitney U test, and Jonckheere-Terpstra test were performed for the analysis. Results: Substantial percentage improvements were observed from the patient cohort, with the triple application group reporting the highest percentage improvement. Statistically significant differences were presented in all application groups. No adverse events were reported. Discussion: This study provided preliminary findings that UCTas are a safe, minimally invasive application for cervical paraspinal defects. Notable limitations included a lack of a direct comparison group and a small sample size. Conclusion: This study highlights the need for continued research to validate the preliminary results for the safety, feasibility, and efficacy of umbilical cord tissue allografts in patients with cervical paraspinal defects.

  • Open Access

    An Observational Study of Human Umbilical Cord Tissue Allografts for Paraspinal Muscle and Entheses Defects in the Thoracic and Lumbar Regions

    by Conrad Tamea, Jeff Buchalter, Jason Capra, Tracie Gilliland, Naomi Lambert, Alexis Lee, Tyler Barrett

    Introduction: With age and injury, the infiltration of fat in the paraspinal muscles can cause degeneration, disorganizing the structural integrity of the connective tissue, causing lower back pain (LBP). Human umbilical cord tissue allografts (UCTa) have a collagen-rich matrix with various ECM components that can replace damaged connective tissue. The objective of this study is to evaluate preliminary findings on the safety and efficacy of UCTa for the supplementation of degenerated tissue in thoracic and lumbar paraspinal muscles refractory to standard conservative methods. Materials and Methods: A total of 141 patients from an observational repository were identified with paraspinal muscle degeneration. Patients received one to three applications of UCTa, outcomes were tracked using the Numeric Pain Rating Scale, the Western Ontario and McMaster University Arthritis Index, and the Quality-of-Life Scale. Results: All groups showed positive improvement in the NPRS and WOMAC scales. Multi-application groups revealed statistically significant differences in the analyses. No adverse events or complications were reported. Discussion: Limitations included a lack of a control group and the increase of recall and response bias due to using patient-reported measures. Conclusion: This pilot investigation highlights the need for continued research through randomized controlled trials to validate efficacy, establish optimal dosage protocols, and compare UCTa to other conservative interventions.

  • Open Access

    Wharton’s Jelly Tissue Allograft for Connective Tissue Defects Surrounding Nerves in the Tarsal Tunnel: A Retrospective Case Series

    by Ronald Bruton, Tracie L. Gilliland, John J. Shou, Crislyn G. Woods, Naomi E. Lambert, Tyler C. Barrett

    Caused by age or trauma, collapsed connective tissue can cause nerve entrapment and damage within the tarsal tunnel. Tarsal tunnel syndrome is relatively underdiagnosed. This study presents an intervention targeting damaged tissues surrounding the nerves and replacing the structural cushioning with a Wharton’s jelly tissue allograft. The eight patients in our study, selected from four clinical sites, had tarsal tunnel-related defects. Patient outcomes were tracked on a 90-day calendar utilizing the Numeric Pain Rating Scale (NPRS) and the Western Ontario and McMaster University Arthritis Index (WOMAC). All patients had failed standard care practices for at least six weeks. Each patient received a Wharton’s jelly tissue allograft to sites around the affected tarsal tunnel. No patients experienced adverse reactions. The percent change results calculated from the initial application to the 90-day follow-up showed an improvement of 59.43% in NPRS and a 37.58% improvement in WOMAC. This study provides evidence that WJ allograft applications are safe, minimally invasive, and efficacious for patients who have failed standard care treatments for tissue defects associated with tarsal tunnel syndrome. The limitations of this study include its small cohort size and nonblinded nature. The results of this study warrant further research to confirm the efficacy, optimal dose, protocol, and durability of Wharton’s jelly.

  • Open Access

    Wharton’s Jelly Tissue Allograft for Connective Tissue Defects Surrounding Nerves in the Tarsal Tunnel: A Retrospective Case Series

    by Ronald Bruton, Tracie Gilliland, John Shou, Naomi Lambert, Crislyn Woods, Tyler Barrett

    Caused by age or trauma, collapsed connective tissue can cause nerve entrapment and damage within the tarsal tunnel. Tarsal tunnel syndrome is relatively underdiagnosed. This study presents an intervention targeting damaged tissues surrounding the nerves and replacing the structural cushioning with a Wharton’s jelly tissue allograft. The eight selected patients from four clinical sites had tarsal tunnel-related defects. Patient outcomes were tracked on a 90-day calendar utilizing the Numeric Pain Rating Scale (NPRS) and the Western Ontario and McMaster University Arthritis Index (WOMAC). All patients had failed standard care practices for at least six weeks. Each patient received a Wharton’s jelly tissue allograft to sites around the affected tarsal tunnel. No patients experienced adverse reactions. Percent change calculated from the initial application to the 90-day follow-up showed an improvement of 59.43% in NPRS and a 37.58% improvement in WOMAC. T his study provides evidence that WJ allograft applications are safe, minimally invasive, and efficacious for patients who have failed standard care treatments for tissue defects associated with Tarsal Tunnel syndrome. Limitations include the small cohort size and nonblinded nature. The results of this study warrant further research to confirm the efficacy, optimal dose, protocol, and durability of Wharton's jelly.